Alto Neuroscience Announces Initiation of Phase 2 Study of A

Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder and higher levels of anhedonia


ALTO-203...

Related Keywords

, Jessica Powell , Exchange Commission , Alto Neuroscience Inc , Alto Neuroscience , Precision Psychiatry Platform , Bond Lader Visual Analog Scale , Private Securities Litigation Reform Act , Annual Report ,